Similarly, a TGR5 agonist that is capable of inducing the secretion of GLP-1 as well as increasing energy expenditure may prove to be a promising incretin-based strategy for the treatment of type 2 diabetes and obesity [26,27]. The gene discussed is GPBAR1; the disease is Obesity.